Praveen Tyle's most recent trade in Kiora Pharmaceuticals Inc was a trade of 30,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | Praveen Tyle | Director | Purchase of securities on an exchange or from another person at price $ 3.96 per share. | 19 Aug 2024 | 5,000 | 5,014 (0%) | 0% | 4.0 | 19,800 | Common Stock |
| Kiora Pharmaceuticals Inc | Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 28,690 | 57,380 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 28,690 | 137,351 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 26,600 | 26,600 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 26,600 | 108,661 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 16,560 | 120,791 (0%) | 0% | 7.2 | 119,066 | Common Stock |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 9,727 | 82,061 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 9,727 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,990 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 2,990 | 72,334 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 96,310 | 96,310 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Praveen Tyle | EVP, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 32,100 | 32,100 | - | - | Restricted Stock Units | |
| Kiora Pharmaceuticals Inc | Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 3,333 | 3,333 | - | - | Stock Option (right to buy) |